今年以来，港股市场表现亮眼，截至6月11日收盘，恒生指数、恒生科技指数累计涨幅均超21%，恒生 指数成分股中总市值超1万亿港元的股票均上涨，涨幅最大的比亚迪股份累计涨逾60%，总市值最大的 腾讯控股累计涨逾25%。南向资金持续加仓港股市场，今年以来累计净流入超6700亿港元，创历史同期 新高。 近日，中信证券、华泰证券、国泰海通等多家券商机构召开2025年中期策略会。对于下半年的港股市 场，机构人士认为，国内政策发力驱动基本面修复，港股有望延续震荡向上趋势，南向资金在下半年仍 将持续增配港股市场，红利、科技、新消费等方向有望受青睐。 港股市场表现亮眼 在DeepSeek引领中国资产重估叙事的大背景下，今年以来港股市场表现全球领先。不过，受海外因素 扰动，其在4月一度出现明显回调。 截至6月11日收盘，恒生指数、恒生中国企业指数、恒生科技指数今年以来分别累计上涨21.47%、 21.62%、22%，领涨全球主要市场。 ● 本报记者 吴玉华 胡雨 对于今年以来港股市场上涨的原因，中金公司研究部海外策略首席分析师刘刚认为，当前中国有结构亮 点的宏观与市场环境更有利于港股，这是因为无论是提供稳定回报的分红，还是作为结 ...

Core Viewpoint - WuXi Biologics (02269) shows strong performance with a stock price of HKD 26.4, up 1.54%, indicating continued capital inflow and strong short-term momentum [1] Technical Analysis - The stock is in a bullish pattern with key resistance at HKD 27.5; a breakthrough could lead to a challenge of HKD 29, while support is at HKD 24.7, presenting a potential buying opportunity [1] - The 10-day, 30-day, and 60-day moving averages are in a bullish arrangement, suggesting a positive medium-term trend [1] - The MACD has shown a golden cross and continues to expand, indicating further upward potential, although the RSI is nearing overbought levels [1] - Current technical signals include 15 buy signals, 6 neutral signals, and 3 sell signals [1] Product Performance - On June 6, 2025, WuXi Biologics' stock rose 7.1% over two days, leading to strong performance in related warrants, with UBS bull certificates (56751) rising 43% and JPMorgan bull certificates (57118) increasing by 38% [3] - For those optimistic about WuXi Biologics breaking through HKD 27.5, low-premium, high-leverage call options are recommended, such as HSBC call option (14447) with a strike price of HKD 29.15 [5] Investment Opportunities - In the bull certificate market, JPMorgan bull certificate (57118) offers a leverage of 4.4 times with a recovery price of HKD 22, while UBS bull certificate (56751) has a recovery price of HKD 22.5 [9] - For bearish strategies, UBS bear certificate (57177) provides 5 times leverage with a recovery price of HKD 30, and Societe Generale bear certificate (58298) also offers 5 times leverage with a recovery price of HKD 30.5 [9]

Core Insights - The total trading volume of non-monetary ETFs reached 272.705 billion CNY, with 62 ETFs exceeding 1 billion CNY in trading volume [1] - The Hong Kong Innovative Drug ETF, Short-term Bond ETF, and Credit Bond ETF led the market in trading volume, with respective volumes of 13.208 billion CNY, 12.052 billion CNY, and 9.988 billion CNY [1] - The Hong Kong Innovative Drug ETF (513120.SH) has a latest share size of 9.148 billion CNY and closely tracks the Hong Kong Innovative Drug CNY Index [1] Trading Volume and Performance - The Hong Kong Innovative Drug ETF saw a trading volume increase of 166.52% compared to the previous trading day, with an average trading volume of 5.319 billion CNY over the last 5 days [2] - The Short-term Bond ETF (511360.SH) also experienced a trading volume increase of 22.23% compared to the previous trading day, with a latest share size of 433 million CNY [2] - The Hong Kong Innovative Drug ETF Fund (520700.SH) had a trading volume increase of 328.35% compared to the previous trading day, with a latest share size of 256 million CNY [3] Turnover Rate - The Benchmark National Debt ETF had the highest turnover rate at 460.37%, followed by the Hong Kong Medical ETF at 394.29% and the Hong Kong Innovative Drug ETF Fund at 261.80% [7] - The Hong Kong Innovative Drug ETF also showed a significant increase in turnover rate, rising by 143.03% compared to the previous trading day [2] Sector and Index Tracking - The Hong Kong Innovative Drug ETF tracks the Hong Kong Innovative Drug CNY Index, which includes up to 50 listed companies involved in innovative drug research and development [1] - The Short-term Bond ETF tracks the China Securities Short-term Bond Index, reflecting the overall performance of investment-grade short-term bonds [2] - The Hong Kong Medical ETF tracks the Hong Kong Stock Connect Medical Care Index, which includes companies involved in pharmaceuticals, biotechnology, and medical services [9]

2025年已行至年中，港股市场在经历上半年"脉冲式反弹"后，下半年走势成为投资者关注焦点。 此外，港股估值水平长期处于相对低位，也是今年上半年港股市场走强的原因之一。据中信证券研究， 目前港股整体估值水平相对合理，成长板块的估值处于历史相对较低水平。在国内经济持续复苏，AI 对业绩催化的预期下，以及预计更多优质企业赴港上市的背景下，下半年港股整体的估值水平仍有望进 一步抬升。 多家券商机构展望下半年行情 对于下半年的港股市场行情，中信证券认为，尽管关税政策仍可能对港股基本面造成影响，但近期关税 扰动缓和已带来市场情绪的抬升，且中美贸易摩擦对港股基本面影响相对有限，企业盈利仍具韧性；而 在港股上市制度改革深化的背景下，预计优质企业赴港上市也将进一步提升港股市场的资产质量及流动 性水平；南向资金或也将持续流入港股市场带来支撑。考虑到中美博弈仍具复杂性，且外围市场不确定 性尚存，三季度港股或呈震荡向上的趋势。而四季度预计随着国内稳增长政策的加码带来港股业绩上修 的契机；以及AI产业催化的落地重塑科技板块估值，叠加全球流动性环境改善，港股或迎来估值和盈 利的双重修复。 中金公司表示，当前中国整体仍需修复但有结构亮点的 ...

2025年已行至年中，港股市场在经历上半年"脉冲式反弹"后，下半年走势成为投资者关注焦点。 近日，中金公司、中信证券、国泰海通等多家券商机构发布了港股下半年策略报告，多家机构认为，港股将延 续震荡向上趋势，高股息资产、科技互联网、新消费等方向有望受青睐。 多重因素推动港股市场走强 回顾今年上半年港股市场行情，在DeepSeek引领中国资产重估叙事的大背景下，港股表现全球领先。不过， 受美国所谓的"对等关税"扰动，市场在反弹与回调中循环往复。 截至目前，恒生指数年内涨幅为20.45%，恒生科技指数的年内涨幅为20.68%。个股方面，恒生指数成份股中 的石药集团、周大福、翰森制药、小米集团、比亚迪股份、药明生物、网易等多股年内涨幅超过50%。 今年上半年，DeepSeek引发AI热潮助推中国资产重估，推动港股市场一度领涨全球，随后，由于部分中国科 技龙头股的资本开支计划不及预期，科技重估叙事有所降温。中金公司认为，后续需要更多催化剂，尤其是跨 越式的模型迭代或突破性的应用落地。中短期来看，AI趋势主要通过拉动资本开支推动私人部门信用扩张， 2025年AI相关新增资本开支预计约1500亿元。 中金公司表示，当前中国 ...

Group 1 - The innovative drug sector in Hong Kong continues to rise, with related ETFs showing significant gains, averaging around 3% in half-day trading and a total transaction amount exceeding 1 billion yuan [1][2] - The Hong Kong Medicine ETF (513200) recorded a half-day transaction amount of 474 million yuan, indicating active trading [1][3] - The number of pharmaceutical companies included in the Hong Kong Stock Connect has reached nearly 100, accounting for over 40% of the total pharmaceutical companies listed in Hong Kong [3] Group 2 - The average holding ratio of the top ten pharmaceutical stocks by Northbound funds is around 40%, reflecting sustained buying interest from mainland investors [3] - The valuation of the Hong Kong pharmaceutical sector has been contracting since mid-2021, with some quality companies' PE ratios nearing historical lows, suggesting limited downside risk for their stock prices [3] - The Hong Kong Medicine ETF (513700) and the Hong Kong Stock Connect Medicine ETF (513200) have seen half-day gains of 3.4% and 3.36%, respectively, with the latter's scale reaching 2.73 billion shares [3][4] Group 3 - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index selects 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [3] - Major weighted stocks in the index include Innovent Biologics (11.09%), BeiGene (10.33%), and WuXi Biologics (9.31%), among others [5][6]

Group 1 - The Hang Seng Medical Index ETF has shown active trading with a turnover of 14.61% and a transaction volume of 40.57 million yuan, indicating a vibrant market activity [3] - Over the past two weeks, the Hang Seng Medical Index ETF has experienced a significant growth in scale, increasing by 4.21 million yuan, ranking in the top third among comparable funds [3] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 27.7 times, which is at a historical low, being below 91.86% of the time over the past three years [3] Group 2 - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.95% of the index, with notable companies including Innovent Biologics, BeiGene, and WuXi Biologics [3] - Recent government policies aim to enhance and improve public health services, including adjustments to the basic medical insurance drug list and the introduction of innovative drug lists for commercial health insurance [3] - Industry experts anticipate that the medical innovation sector is entering a harvest period, with a clear trend of performance and valuation recovery expected in the second half of the year [3] Group 3 - Yangtze Securities highlights that favorable domestic policies are emerging to encourage high-quality innovation, which may drive rapid growth in corporate performance [4] - The valuation levels of domestic innovative drugs are low, with some products showing potential to be the best in their class globally, suggesting a positive outlook for international market expansion [4] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [4]

Group 1 - The core viewpoint of the news is that the Hong Kong innovative drug sector is experiencing significant growth, driven by multiple factors including clinical data breakthroughs, strengthened overseas expectations, policy benefits, and valuation recovery [1][2]. - The Hong Kong Innovative Drug 50 ETF (513780) has seen a price increase of over 4% on June 10, with a year-to-date gain exceeding 60% and a trading volume surpassing 500 million [1]. - The recent policy issued by the Central Office and State Council aims to enhance the sharing of quality medical resources and improve the basic medical insurance drug catalog, which is expected to be a substantial driver for pharmaceutical companies, particularly innovative drug firms [1]. Group 2 - The fund manager of the Hong Kong Innovative Drug 50 ETF, Jin Huang, attributes the recent surge in the sector to four key factors: clinical data breakthroughs, enhanced overseas expectations, policy benefits, and valuation recovery [2]. - Despite the significant rise, the price-to-earnings ratio of the China Securities Hong Kong Innovative Drug Index remains around 28 times, which is notably lower than the A-share innovative drug sector's ratio of approximately 45 times, indicating clear recovery potential [2]. - The net inflow into the Hong Kong pharmaceutical sector has exceeded 40 billion HKD this year, providing substantial support for the innovative drug sector [2].

Investment Rating - The report assigns a rating of "Buy" to Hansoh Pharmaceutical (3692 HK) with a target price of HKD 29.30 [6][8]. Core Insights - Hansoh Pharmaceutical has successfully entered into an overseas licensing agreement with Regeneron, which includes an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion, along with royalties on sales [6][8]. - The report highlights the strong performance of the new consumption stocks, particularly the significant price increases of companies like Blok (325 HK) and the mixed performance of Gu Ming (1364 HK) and Mixue Group (2097 HK) after being included in the Hong Kong Stock Connect [3][4]. - The healthcare sector, particularly the biotech companies, has shown robust growth, with the Hang Seng Healthcare Index rising by 4.8%, outperforming the Hang Seng Index [4]. Summary by Sections Macro Dynamics - The new housing transaction volume in major cities has seen a year-on-year decline of 18.1%, indicating a weakening real estate market [2]. Industry Dynamics - The new consumption sector has been positively impacted by the inclusion in the Hong Kong Stock Connect, with notable stock price increases [3]. - The AI sector is gaining traction, with Fourth Paradigm (682 HK) seeing a 9.7% increase due to positive quarterly results and new AI solutions for the healthcare industry [3]. Healthcare Sector - The healthcare index has outperformed the broader market, with significant gains from companies like Innovent Biologics (1801 HK) and others, driven by new drug approvals and clinical trial successes [4]. - The report emphasizes the potential of Hansoh Pharmaceutical's new drug HS-20094, which has completed several Phase II clinical trials and is recognized for its quality by Regeneron [6][8]. Energy Sector - The report suggests a cautious approach towards the new energy sector, with mixed performances observed in solar stocks and a positive outlook for coal-fired power generation due to low coal prices [10][11]. - The nuclear energy sector is expected to benefit from increased demand for uranium, driven by U.S. initiatives to boost domestic nuclear energy production [13][15].

Core Viewpoint - The innovative pharmaceutical sector, particularly the Hong Kong Stock Connect innovative drug segment, is experiencing significant growth, with the index and major stocks showing strong upward trends [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug index (987018) has risen by 1.38%, with key stocks like Tigermed (03347) increasing over 7% and others like Kanglong Chemical (03759) and 3SBio rising over 5% [1]. - The Hong Kong Stock Connect innovative drug ETF (159570) has seen a 2.7% increase, with trading volume surpassing 700 million yuan, marking a historical high [1][3]. - Over the past five days, the Hong Kong Stock Connect innovative drug ETF has attracted a total net inflow of 736 million yuan, averaging 147 million yuan daily [3]. Group 2: Investment Trends - Leverage funds are increasingly being utilized, with the latest financing buy-in for the Hong Kong Stock Connect innovative drug ETF reaching 222 million yuan [3]. - The upcoming American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase a growing number of Chinese pharmaceutical companies, with 73 studies selected for oral presentations in 2025 [3]. Group 3: Sector Analysis - Domestic innovative drugs are gaining competitive strength in the global market, with international investors showing increasing confidence in Chinese pharmaceutical companies [3]. - The Hong Kong Stock Connect innovative drug ETF (159570) has a significant focus on the innovative drug industry, with the top ten holdings accounting for nearly 72% of the total weight [4][5]. - The ETF is characterized by a high concentration in innovative drugs, with an 85% weight in this category, and is considered undervalued compared to historical sales ratios [5].